Support Line: 0800 002 9002
General Enquiries: 01223 870008

News Archive

Kidney Cancer News

Kidney Cancer UK secure landmark kidney cancer NICE clinical guideline

Kidney Cancer UK secure landmark kidney cancer NICE clinical guideline

Kidney Cancer UK, the UK’s leading kidney cancer charity has, through its approach to NHS England, secured a ...
NHS gives GP teams direct access to tests to speed up cancer diagnosis

NHS gives GP teams direct access to tests to speed up cancer diagnosis

NHS Press Release (16th November 2022) Tens of thousands of cancers could be detected sooner each year thanks to ...
Pembrolizumab recommended as an adjuvant therapy for RCC across UK

Pembrolizumab recommended as an adjuvant therapy for RCC across UK

The Scottish Medical Consortium have recommended Pembrolizumab (Keytruda) as a monotherapy which is indicated for ...
Kidney Cancer Patient Survey 2022

Kidney Cancer Patient Survey 2022

Thank you for taking part in our 9th annual UK focused Kidney Cancer Patient Survey 2022. This survey is now ...
Highlights from the ESMO Congress 2022

Highlights from the ESMO Congress 2022

We are delighted to share with you the report from The European Society of Medical Oncology (ESMO) congress 2022 ...
The Challenges and Opportunities for Kidney Cancer Care Recovery report

The Challenges and Opportunities for Kidney Cancer Care Recovery report

In anticipation of the Government’s upcoming 10-year Cancer Plan, Kidney Cancer UK is pleased to welcome the publication of the report – ‘The Challenges and Opportunities for Kidney Cancer Care Recovery’.
Opdivo + Yervoy fails adjuvant phase 3 trial

Opdivo + Yervoy fails adjuvant phase 3 trial

Bristol-Myers Squibb has revealed that its checkpoint inhibitor combination of Opdivo and Yervoy failed a phase 3 ...
New Approach to Treating VHL RCC

New Approach to Treating VHL RCC

The research could be used to develop more targeted kidney cancer drugs. Researchers from Sweden’s Karolinska ...
Savolitinib not significantly efficacious in aRCC

Savolitinib not significantly efficacious in aRCC

Savolitinib, alone or in combination with durvalumab, did not demonstrate significant efficacy in patients with ...
4th COVID-19 vaccine safe for immunocompromised

4th COVID-19 vaccine safe for immunocompromised

A fourth dose of mRNA COVID-19 vaccine seems safe for immunocompromised individuals aged 12 years or older, ...
Cabo + nivo & ipi delays kidney cancer progression

Cabo + nivo & ipi delays kidney cancer progression

Adding cabozantinib (Cabometyx) to nivolumab (Opdivo) and ipilimumab (Yervoy) improved progression-free survival ...
Statins improve effectiveness of nivo for advanced kidney cancer

Statins improve effectiveness of nivo for advanced kidney cancer

Statins are widely used in an ageing population, including subjects with solid malignancies. However, no ...